-
2020 CSCO Conference opens, wonderful non-stop!
Time of Update: 2020-10-04
Professor Wang Jie of the Oncology Hospital of the Chinese Academy of Medical Sciences interpreted the RATIONALE 307 study: a Phase III study of patients with advanced squamous non-small cell lung cancer treated with pure chemotherapy first-line chemotherapy, which was first published at this year's ASCO Conference and the latest results were presented at this year's ESMO Conference.
-
CA Cancer J Clin: Revealing the cruel truth that cancer is getting younger! The number of cancer cases among young people has been increasing in the last 10 years.
Time of Update: 2020-10-04
the age group 20-29, the incidence of cancer is 42 and 55 cases per 100,000 population, respectively, and the incidence of cancer among women is 30 per cent higher than that of men.
-
The hoarseness test turned out to be throat cancer, and the doctor warned against these symptoms.
Time of Update: 2020-10-04
And for the larger one-sided T2 or T3 sound door throat cancer, some of the patients can also use the oral laser microscopic surgery, but need to remove a wider range of throat tissue, postoperative tissue defects are more, if not repaired in time, after treatment of the pronunciation effect is relatively poor, hoarse voice serious, patients talk laborily and difficult to identify speech content.
-
Lancet oncol: The quality of life of metastatic despotic prostate cancer patients treated with kabatha.
Time of Update: 2020-10-04
In the CARD study, cabazitaxel (kabatasai) significantly extended the progression-free survival of patients with metastatic degenerative resistance prostate cancer treated with too much cyclocycline and androgen targeted inhibitors.
-
Terisha reduced the risk of brain recurrence by 82% in the early EGFR mutation lung cancer-assisted treatment.
Time of Update: 2020-10-04
A preset exploratory analysis of a Phase III ADAURA clinical study based on positive results showed that AstraZeneza's Terisa (chemical name: Ogini Osimertinib, trade name: Terisa Tagrisso) was in the early stages of undergoing a complete tumor excision (Complementary treatment in patients with non-small cell lung cancer (NSCLC) of EGFRm, a prefrontal growth factor change (EGFRm) in IB, II and IIIA periods, can lead to clinically significant improvements in the disease-free survival of the central nervous system (CNS) (DFS).
-
Real-world research has released the world's first cancer electric field treatment to benefit Chinese patients.
Time of Update: 2020-10-04
On September 12, 2020, at the 4th Annual Meeting and 4th China Cerebral Glioma Academic Conference of the Professional Committee of the Chinese Physicians Association, a forward-looking, one-arm obser
-
Medical College Oncology Hospital Zhang Wei: Don't think it's just an aid, it may affect the whole cancer war.
Time of Update: 2020-10-04
"The rate of nausea and vomiting is still relatively high during anti-tumor treatment, and I want more people to know that we already have a lot of good anti-spitting drugs and need to explore a more
-
Nat Commun: French scientists have discovered a new drug-resistant treatment strategy for cancer immunotherapy.
Time of Update: 2020-10-04
study, the authors found that anti-GARP:TGF-beta-1mAb, in combined with PD-1 blockers, significantly enhanced the effects of tumor T cells and prevented tumor recurrence.
-
Acta Neuropathologica: C11orf95-RELA reprogrammed the 3D epigenome of the on-screen chamber membrane tumor.
Time of Update: 2020-10-04
paper, the authors' team found that the C11orf95 component of the fusion protein determines DNA binding activity, while the RELA component is necessary to drive gene expression associated with tratermoblastoma.
-
Blood:piRNA-30473 promotes DLBCL occurrence and poor prognosmation by regulating m6A RNA methylation.
Time of Update: 2020-10-04
, the piRNA-30473/WTAP/HK2 axis is involved in the occurrence of DLBCL by regulating m6A RNA methylation.
, using a comprehensive analysis of clinical data and data sets from the study, the researchers found that the m6A regulatory gene piRNA-30473 and WTAP improved survival prediction in DLBCL patients.
-
Cell Death Dis: PLCɛ is critical to maintaining the function of AR signals in prostate cancer.
Time of Update: 2020-10-04
the study found that PLCɛ (phospholipidase C) was highly expressed in CaP samples, and that this high expression level was closely related to the activity of ar signal transduction path.
these effects eventually lead to the weakening of AR signals in CaP and inhibit AR-driven cell migration and invasion.
-
CSCO 2020 Look: What's the busiest PI, do you know?
Time of Update: 2020-10-04
In the field of oncology in China, gastric cancer experts have "North Shen, South Li" Ya, "North Shen" refers to Professor Shen Lin of Peking University Cancer Hospital, "South Li" refers to The Shanghai Oriental Hospital well-known oncologist, former chairman of CSCO Professor Li Jin.
-
Br J Cancer: Tall and high risk of these cancers!
Time of Update: 2020-10-04
, the study aims to analyze the gender-specific association between height and 24 site-specific cancers and assess whether the association is related to IGF-1.
men's height was associated with cancer risk Researchers found a positive correlation between male height and the risk of all-cause cancer and five sites (lung, lymphatic, leukemia, non-Hodgkin's lymphoma and melanoma).
-
Despite the smoke has a second trick, reduce the risk of lung cancer, shaking sound public welfare challenge perfectly closed.
Time of Update: 2020-10-04
In order to promote the concern of all sectors of society on the dangers of tobacco and small cell lung cancer, and to call on the general public, especially young people, to stay away from tobacco an
-
NEJM: Oghidini as an EGFR mutation-positive NSCLC postoperative auxiliary therapy, patients significantly benefit.
Time of Update: 2020-10-04
Data updated by 's hypothetical CNS and non-CNS recurrence rates ADAURA studies show that reduced risk of local and distant recurrence, as well as improvements in CNS DFS, further support for Oghidini-assisted therapy as an efficient, practice-changing treatment strategy for EGFR gene mutation-positive I.B.III.A NSCLC patients after tumor complete removal.
-
Nat Commun: VAV2 promotes the regenerative proliferation of squamous cell carcinoma in the skin and head and neck.
Time of Update: 2020-10-04
cancer-promoting effects of the VAV2 signal was found by researchers who found that the catalytic dependence and RHO GTPase dependence function were mediated by c-Myc and YAP/TAZ dependent regenerative proliferation and cell non-differentiation-related transcription.
-
Rongchang Bio-Virdixito monoanti (RC48) treatment of urethra skin cancer was recognized by the FDA breakthrough therapy.
Time of Update: 2020-10-04
the FDA's breakthrough therapy determination means that the clinical data of the new drug show significant efficacy compared to existing treatments, which will accelerate the process of clinical development and meet the needs of patients at an early time.
-
J Vasc Surg: 20 years of single-center follow-up results, the first generation of stent cavity repair aneurysm overall results.
Time of Update: 2020-10-04
to explore the prognosis for the first generation of stent implants (Vanguard) to treat patients with abdominal aortic aneurysms (AAA), researchers from Finland shared the results of a 20-year follow-up at a single center.
-
Clin Cancer Res: Antimalarial drug chloroquine increases the sensitivity of GNAQ/11 mutant melanoma to MEK1/2 inhibitors!
Time of Update: 2020-10-04
This study aims to evaluate the role of chloroquine (lysosome inhibitors, antimalarial drugs) or hydroxychloroquine combined MAP kinase pathps to inhibit the effects of GNAQ/11 mutant cells in and outside the body, and to clarify the mechanism of action of MEK1/2 inhibitors combined with chloroquine induced cytotoxicity.
-
Lancet oncol: The long-term efficacy of postoperative ancillary therapy for the maintenance of high-risk melanoma is significantly better than that of Ipi monoanti.
Time of Update: 2020-10-04
4-year recurrence-free survival rates in the Navu monoantigroup and the Ipi monoantigroup were 51.7% and 41.2%, respectively (risk ratio of 0.71, 95% CI 0.60-0.86, p=0.0003).
